ADC Development Services Targeting CD30

Recently, antibody-drug conjugates (ADCs) are considered as a type of effective and promising strategy for targeted cancer therapy, which presents significant advantages compared with traditional therapy methods. Creative Biolabs is experienced in the field of antibody production and bio-conjugation, and we provide a fully integrated ADCs development service targeting the CD30 biomarker. Our professional team is optimized to help you with high-quality and cost-effective service to make your project a success.

Introduction of CD30

CD30 (also known as TNFRSF8) was first identified as an antigen expressed on Hodgkin and Reed-Sternberg cells of Hodgkin's disease in 1992. It belongs to the TNF receptor (TNFR) superfamily, which is a type I transmembrane glycosylated protein. CD30 mainly expresses on virus-infected lymphocytes, tumor cells of lymphoid origin and activated T cells. It plays an important role in the activation of NF-κB signal by interacting with TRAF2 and TRAF5. As a receptor, CD30 also involves in the regulation of apoptosis and the proliferation of autoreactive CD8+ effector T cells to protect the body from autoimmunity diseases. Moreover, the protein is a important marker associated with some lymphomas, such as the anaplastic large cell lymphoma (ALCL), and it is a target used in immunotherapy especially the ADCs development.

CD30L regulates Th17 differentiation. Fig.1 CD30L regulates Th17 differentiation. (Sun, 2010)

Anti-CD30 ADC for Lymphomas

ADCs have been designed to target the CD30 in the treatment of lymphomas, such as the ALCL and Hodgkin lymphoma (HL). Brentuximab vedotin (SGN-35) is an ADC approved for using in ALCL and HL, which is composed of an anti-CD30 antibody and a potent toxic microtubule-disrupting agent monomethyl auristatin E (MMAE). After clinical trials, most patients with refractory or relapsed systemic ALCL and HL have obtained effective outcome and acceptable toxicity profile. Moreover, the ADC was approved in 2011 for the treatment of refractory and relapsed HL and ALCL.

Another ADC based on CD30 is anti-CD30-LDM, which is a novel ADC consisting of an anti-CD30 monoclonal antibody and Lidamycin (LDM). Preclinical trials demonstrated that the ADC has highly cytotoxic activity to HL and ALCL cell lines with no discernible adverse effects. Thus, this ADC could be a promising candidate for the treatment of ALCL and HL.

Crizotinib enhances anti-CD30-LDM induced antitumor efficacy in NPM-ALK positive anaplastic large cell lymphoma. Fig.2 Crizotinib enhances anti-CD30-LDM induced antitumor efficacy in NPM-ALK positive anaplastic large cell lymphoma. (Wang, 2019)

What Can We Do for You?

As an experienced antibody production and drug discovery company, Creative Biolabs offers a large variety of customized ADCs development services. The goal of our services is to help promote you ADC project in a time and cost effcient way by taking advantage of our expertise and innovative technology platforms. Our ADCs development services including:

For more detailed information, please feel free to contact us.


  1. Sun, X.; et al. CD30 ligand/CD30 plays a critical role in Th17 differentiation in mice. The Journal of Immunology. 2010, 185(4): 2222-2230.
  2. Wang, R.; et al. Crizotinib enhances anti-CD30-LDM induced antitumor efficacy in NPM-ALK positive anaplastic large cell lymphoma. Cancer letters. 2019, 448: 84-93.

For lab research use only, not for any in vivo human use.

Related Sections

ADC Development for Lymphoma: Disease Research:
Online Inquiry
*E-mail Address:
*Products or Services Interested:
Project Description:
*Verification Code:
Please input "biolabs"(case insensitive) as verification code.

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.

Contact us
 45-1 Ramsey Road, Shirley, NY 11967, USA
 Tel: 1-631-357-2254
 Fax: 1-631-207-8356
Heidenkampsweg 58, 20097 Hamburg, Germany
 Tel: 44-207-097-1828